share_log

Analyzing Cue Health (NASDAQ:HLTH) and Nautilus Biotechnology (NASDAQ:NAUT)

Defense World ·  Dec 17, 2022 01:21

Cue Health (NASDAQ:HLTH – Get Rating) and Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Cue Health and Nautilus Biotechnology, as provided by MarketBeat.com.

Get Cue Health alerts:
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cue Health 0 1 3 0 2.75
Nautilus Biotechnology 0 2 0 0 2.00

Cue Health currently has a consensus price target of $7.00, suggesting a potential upside of 139.73%. Nautilus Biotechnology has a consensus price target of $4.00, suggesting a potential upside of 158.06%. Given Nautilus Biotechnology's higher possible upside, analysts plainly believe Nautilus Biotechnology is more favorable than Cue Health.

Insider and Institutional Ownership

37.9% of Cue Health shares are owned by institutional investors. Comparatively, 46.1% of Nautilus Biotechnology shares are owned by institutional investors. 29.4% of Cue Health shares are owned by insiders. Comparatively, 41.3% of Nautilus Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Cue Health and Nautilus Biotechnology's net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cue Health -24.25% -12.29% -8.93%
Nautilus Biotechnology N/A -17.79% -16.17%

Risk & Volatility

Cue Health has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.

Valuation & Earnings

This table compares Cue Health and Nautilus Biotechnology's top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cue Health $618.11 million 0.71 $86.42 million ($0.88) -3.32
Nautilus Biotechnology N/A N/A -$50.31 million ($0.49) -3.16

Cue Health has higher revenue and earnings than Nautilus Biotechnology. Cue Health is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Summary

Cue Health beats Nautilus Biotechnology on 7 of the 13 factors compared between the two stocks.

About Cue Health

(Get Rating)

Cue Health Inc., a healthcare technology company, designs and develops diagnostic platform for diagnostic tests for individuals, enterprises, healthcare providers and payors, and public health agencies. The company offers Cue Integrated Care platform comprising hardware and software components, such as Cue Health Monitoring System consisting of Cue Reader, a portable and reusable reader, Cue Cartridge, a single-use test cartridge, and Cue Wand, a sample collection wand; Cue Data and Innovation Layer, a solution with cloud-based data and analytics capability; Cue Virtual Care Delivery Apps, which include Cue Health App and Cue Enterprise Dashboard; and Cue Ecosystem Integrations and Apps, a solution that allows integrations with third-party applications and sensors. It also provides COVID-19 testing kits for the Cue Health Monitoring System The company was formerly known as Cue Inc and changed its name to Cue Health Inc. in December 2017. Cue Health Inc. was incorporated in 2010 and is headquartered in San Diego, California.

About Nautilus Biotechnology

(Get Rating)

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

Receive News & Ratings for Cue Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Health and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment